Probiotics and Antimicrobial Proteins

, Volume 7, Issue 3, pp 203–206 | Cite as

Effective Treatment of Staphylococcal Scalded Skin Syndrome with Platelet Microbicidal Protein in CBRB-Rb(8.17)1Iem Mice Model

  • Sergey A. Miroshnikov
  • Viktor A. Gritsenko
  • Iuri B. IvanovEmail author


Skin and soft-tissue infections are among the most common infections. Staphylococcus aureus may cause a number of toxin-mediated diseases, including staphylococcal scalded skin syndrome (SSSS). The therapeutic efficacy of some antimicrobial peptides was recently evaluated in a mouse model of SSSS. This study is the first in vivo demonstration of the use of PMP to improve outcome of SSSS. Twenty-four CBRB-Rb(8.17)1Iem female mice naturally infected by endogenous S. aureus with SSSS symptoms were used in this work and divided into two equal groups. From neck of each mouse was isolated and identified endogenous exfoliative producing strain of S. aureus. PMP was obtained from human platelets and tested against Bacillus subtilis ATCC 6633. PMP had bactericidal activity against B. subtilis ATTC 6633 and endogenous strain of S. aureus at 2.0 ± 0.5 and 14.5 ± 0.5 µg/ml, respectively. At 4 weeks, the mice of experimental group were treated subcutaneous near exfoliative zone with 0.2 ml of PMP in final concentration 10 µg/ml every day. Control mice was injected with 0.2 ml 0.9 % NaCl. At 1 day of experiment maximal zone of alopecia was at PMP-treating group (380 ± 20 mm2) in comparison with control group (167 ± 10 mm2, p < 0.01). At 50 day of observation (22nd day after the end of treatment), the square of alopecia in control group was 1220 ± 40 mm2 in comparison with 870 ± 17 mm2 in experimental group (p < 0.01). The antistaphylococcal in vivo activity of PMP demonstrated in present study makes these molecules potentially useful for treatment of SSSS.


Staphylococcal scalded skin syndrome Mice model Platelet microbicidal protein Treatment 



Research was done with financial support of the Russian Science Foundation (Grant No. 14-36-00023).

Conflict of interest

The authors declare no conflict of interest.


  1. 1.
    Afshar M, Gallo RL (2013) Innate immune defense of the skin. Vet Dermatol 24:32–38.e8–9. doi: 10.1111/j.1365-3164.2012.01082.x
  2. 2.
    Baker BS (2006) The role of microorganisms in atopic dermatitis. Clin Exp Immunol 144:1–9CrossRefGoogle Scholar
  3. 3.
    Brook I (2002) Secondary bacterial infections complicating skin lesions. J Med Microbiol 51:808–812Google Scholar
  4. 4.
    Huang HN, Pan CY, Chan YL et al (2014) Use of the antimicrobial peptide pardaxin (GE33) to protect against methicillin-resistant Staphylococcus aureus infection in mice with skin injuries. Antimicrob Agents Chemother 58:1538–1545CrossRefGoogle Scholar
  5. 5.
    Ivanov IB (2005) In vitro resistance to human platelet microbicidal protein among urethral staphylococcal and enterococcal isolates with its correlation with prostatitis. Indian J Med Microbiol 23:253–255Google Scholar
  6. 6.
    Ivanov IB, Gritsenko VA (2009) Comparative activities of cattle and swine platelet microbicidal proteins. Probiotics Antimicrob Proteins 1:148–151CrossRefGoogle Scholar
  7. 7.
    Iwatsuki K, Yamasaki O, Morizane S et al (2006) Staphylococcal cutaneous infections: invasion, evasion and aggression. J Dermatol Sci 42:203–214CrossRefGoogle Scholar
  8. 8.
    Jenssen H, Hamill P, Hancock REW (2006) Peptide antimicrobial agents. Clin Microbiol Rev 19:491–511CrossRefGoogle Scholar
  9. 9.
    Kupferwasser LI, Skurray RA, Brown MH et al (1999) Plasmid-mediated resistance to thrombin-induced platelet microbicidal protein in staphylococci: role of the qacA locus. Antimicrob Agents Chemother 43:2395–2399Google Scholar
  10. 10.
    Lin YT, Wang CT, Chiang BL (2007) Role of bacterial pathogens in atopic dermatitis. Clin Rev Allergy Immunol 33:167–177CrossRefGoogle Scholar
  11. 11.
    Myhrman E, Håkansson J, Lindgren K et al (2013) The novel antimicrobial peptide PXL150 in the local treatment of skin and soft tissue infections. Appl Microbiol Biotechnol 97:3085–3096CrossRefGoogle Scholar
  12. 12.
    Moiseeva EV (2005) Original approaches to test anti-breast cancer drugs in a novel set of mouse models. Ph D Thesis, Utrecht UniversityGoogle Scholar
  13. 13.
    Mohamed M, Seleem M (2014) Efficacy of short novel antimicrobial and anti-inflammatory peptides in a mouse model of methicillin-resistant Staphylococcus aureus (MRSA) skin infection. Drug Des Dev Ther 8:1979–1983CrossRefGoogle Scholar
  14. 14.
    Noguchi N, Nakaminami H, Nishijima S et al (2006) Antimicrobial agent of susceptibilities and antiseptic resistance gene distribution among methicillin-resistant Staphylococcus aureus isolates from patients with impetigo and staphylococcal scalded skin syndrome. J Clin Microbiol 44:2119–2125CrossRefGoogle Scholar
  15. 15.
    Novick RP, Geisinger E (2008) Quorum sensing in staphylococci. Annu Rev Genet 42:541–564CrossRefGoogle Scholar
  16. 16.
    Ong PY, Ohtake T, Brandt C et al (2002) Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 347:1151–1160CrossRefGoogle Scholar
  17. 17.
    Schroder J-M, Harder J (1999) Human beta-defensin-2. Int J Biochem Cell Biol 31:645–651CrossRefGoogle Scholar
  18. 18.
    Spellberg B, Powers JH, Brass EP et al (2004) Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 38:1279–1286CrossRefGoogle Scholar
  19. 19.
    Yeaman MR (2010) Platelets in defense against bacterial pathogens. Cell Mol Life Sci 67:525–544CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Sergey A. Miroshnikov
    • 1
  • Viktor A. Gritsenko
    • 2
  • Iuri B. Ivanov
    • 2
    Email author
  1. 1.All-Russian Institute of Meat Cattle BreedingRussian Academy of Agricultural SciencesOrenburgRussia
  2. 2.Institute of Cellular and Intracellular SymbiosisRussian Academy of SciencesOrenburgRussia

Personalised recommendations